Development and Validation of a Cardiovascular Risk Assessment Model in Patients With Established Coronary Artery Disease

2013 ◽  
Vol 112 (1) ◽  
pp. 27-33 ◽  
Author(s):  
Linda Battes ◽  
Rogier Barendse ◽  
Ewout W. Steyerberg ◽  
Maarten L. Simoons ◽  
Jaap W. Deckers ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Coronary Artery Disease ◽  
Cardiovascular Risk ◽  
Coronary Artery ◽  
Assessment Model ◽  
Risk Assessment Model ◽  
Cardiovascular Risk Assessment ◽  
Established Coronary Artery Disease ◽  
Artery Disease ◽  
Development And Validation

scholarly journals Prospective Assessment of Biomarkers of Hypercoagulability for the Identification of Patients With Severe Coronary Artery Disease. The ROADMAP-CAD Study

2020 ◽  
Vol 26 ◽  
pp. 107602962096459
Author(s):  
Grigoris T. Gerotziafas ◽  
Theodoros Zografos ◽  
Ioannis Pantos ◽  
Eleftheria Lefkou ◽  
Audrey Carlo ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Thrombin Generation ◽  
Assessment Tools ◽  
Assessment Model ◽  
Multivariate Logistic Regression Model ◽  
Clotting Time ◽  
Effective Prevention ◽  
Artery Disease

In patients with stable coronary artery disease (CAD) blood hypercoagulability figures among factors leading to thrombosis. Tissue factor (TF) exposure at ruptured plaque initiates blood coagulation and hypercoagulability is responsible for thrombus formation. Early identification of patients eligible for angiography is a challenging issue for effective prevention of ACS. This pilot study aimed to identify biomarkers of hypercoagulability that can be prospectively used in risk assessment tools for the evaluation of CAD severity. Biomarkers of hypercoagulability could be a used for the evaluation of CAD severity. Platelet-poor plasma from 66 patients who were referred to coronary angiography was assessed for thrombin generation, phospholipid-dependent clotting time (Procoag-PPL ® ) and D-Dimers, and evaluated against atherosclerotic burden. Patients with CAD, as compared to controls, showed attenuated thrombin generation lag time: 4.7 (3.8-5.4) min versus 2.5 (2.1-2.9) min; p < 0.0001, shorter Procoag-PPL® clotting time 55.0(32-66) s versus 62.8 (42-85) s; p = 0.001), and higher D-Dimer levels 0.509 (0.27-2.58) μg/ml versus 0.309 (0.23-0.39) μg/ml; p = 0.038. Multivariate logistic regression model showed excellent discriminatory value in predicting CAD severity. The ROADMAP-CAD study showed that the Procoag-PPL® clotting time and thrombin Peak are informative for the the burden of the coronary atherosclerotic disease. The clinical relevance of this observation in the development of a new clinic-biological risk assessment model for early diagnosis of severe CAD has to be examined in a prospective study.

scholarly journals Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease

2014 ◽  
Vol 63 (6) ◽  
pp. 520-527 ◽  
Author(s):  
Michelle L. O'Donoghue ◽  
David A. Morrow ◽  
Sotirios Tsimikas ◽  
Sarah Sloan ◽  
Angela F. Ren ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Lipoprotein A ◽  
Established Coronary Artery Disease ◽  
Artery Disease

scholarly journals Circulating Oxidized LDL is a Useful Marker for Cardiovascular Risk Assessment

Circulation ◽  
2001 ◽  
Vol 103 (suppl_1) ◽  
pp. 1350-1350
Author(s):  
Ann Mertens ◽  
Peter P Verhamme ◽  
Raymond Verhaeghe ◽  
Erik Muls ◽  
Desire Collen ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Risk Assessment ◽  
Coronary Artery Disease ◽  
Cardiovascular Risk ◽  
Coronary Artery ◽  
Cardiovascular Risk Factors ◽  
Oxidized Ldl ◽  
Global Risk ◽  
Artery Disease

0032 BACKGROUND: Coronary artery disease is associated with an increase in circulating oxidized (Ox)LDL (Circulation 1998; 98:1487-1494). OBJECTIVES: 1) To determine the usefulness of OxLDL for identifying cardiovascular disease patients and 2) to study the relation of OxLDL with cardiovascular risk factors. METHODS: 1) To determine the diagnostic value of OxLDL 308 subjects were studied: 178 patients with angiographically proven coronary artery disease and 130 age-matched subjects without cardiovascular disease (controls) confirmed by B mode ultrasonography of their carotid arteries. 2) Additional 307 patients without cardiovascular disease were studied to determine the relation of OxLDL with cardiovascular risk factors. Levels of OxLDL were directly measured in plasma using a mAb-4E6 based competition ELISA. RESULTS: Compared with controls, patients had 2.3-fold higher levels of circulating OxLDL. At a cutoff value of 2.30 mg/dL, the sensitivity of OxLDL for cardiovascular disease was 73% with a specificity of 90%. The Global Risk Assessment Score (GRAS) was calculated using age, total and HDL cholesterol, systolic blood pressure, diabetes mellitus and smoking. GRAS was 8.65±3.41 for patients versus 6.09±5.10 (p≤0.001) for controls. Compared with subjects with low OxLDL (≤2.30 mg/dL) and low GRAS (≤12), risk of having cardiovascular disease was 3.2 times higher for subjects with low OxLDL and high GRAS, 6.4 times higher for subjects with high OxLDL and low GRAS and 27 times higher for subjects with both high OxLDL and high GRAS. Among patients without cardiovascular disease, stepwise multivariate analysis showed that Body Mass Index (p<0.001), LDL cholesterol (p<0.001), diabetes type 2 (p=0.003), triglycerides (p=0.017) and smoking (p=0.046) were the strongest predictors of OxLDL. Conclusion: Circulating OxLDL is a sensitive marker of cardiovascular disease. Circulating oxidized LDL correlates with obesity, hypercholesterolemia, diabetes and smoking. Addition of OxLDL to the established risk factors may improve cardiovascular risk prediction. Inclusion of OxLDL in prospective studies of risk factors of cardiovascular disease seems to be warranted.

Sign in / Sign up

Export Citation Format

Share Document